Radiopharmaceuticals command this premium over small molecules

The theranostic revolution has made radiopharmaceuticals one of the most valuable modalities in biopharma licensing. With built-in companion diagnostics and precision targeting, these assets command significantly higher deal terms than traditional small molecules across all development stages.

Based on analysis of 600+ biopharma licensing deals from 2020-2026